Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer

NCT02648477 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02648477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02648477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 28, 2016
Completion date
December 30, 2023
Enrollment
30 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, estrogen receptor positive, her2/neu negative, progesterone receptor negative, progesterone receptor positive, stage iv breast cancer, triple-negative breast carcinoma